Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.
HUMA - Humacyte, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$2.00
DETAILS
HIGH:
$2.00
LOW:
$2.00
MEDIAN:
$2.00
CONSENSUS:
$2.00
UPSIDE:
393.46%
Stock News
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company's Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D.
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has authorized an extension of the expiration dating period for Symvess® (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated at 2°C to 8°C (36°F to 46°F).
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engin.
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
NEW YORK and NEW ORLEANS, Aug. 21, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –
Head to Head Comparison: Denali Therapeutics (NASDAQ:DNLI) versus Humacyte (NASDAQ:HUMA)
Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk. Analyst Recommendations This is a summary of recent recommendations
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.24 per share a year ago.
Humacyte Q2 Earnings Call Highlights
Humacyte NASDAQ: HUMA reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study.
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 –
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engin.
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and six months ended June 30, 2026, on Wednesday, August 12, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.
Price Targets
BTIG Reiterates Buy Rating on Humacyte (HUMA)
$2.00
(was $0.64)
Ryan Zimmerman
·
BTIG
H.C. Wainwright Reiterates Buy Rating on Humacyte (HUMA)
$3.00
(was $1.35)
Swayampakula Ramakanth
·
H.C. Wainwright
Humacyte price target lowered to $6 from $7 at BTIG
$6.00
(was $1.68)
UBS
Humacyte initiated with an Overweight at Barclays
$3.50
(was $1.47)
Matt Miksic
·
Barclays
Piper Sandler Reiterates Neutral Rating on Humacyte (HUMA)
$6.00
(was $4.86)
Matt O'Brien
·
Piper Sandler
BTIG Reiterates Buy Rating on Humacyte (HUMA)
$10.00
(was $4.86)
Ryan Zimmerman
·
BTIG
Humacyte (HUMA) Stock Gets A $5 Price Target
$5.00
(was $2.21)
Cowen Cowen
·
Cowen & Co.
Humacyte downgraded to Underweight from Overweight at Piper Sandler
$4.00
(was $5.37)
Matt O'Brien
·
Piper Sandler